Tenofovir Disoproxil Fumarate: In Chronic Hepatitis B

ISSN： 0012-6667

Source： Drugs, Vol.69, Iss.16, 2009-11, pp. : 2245-2256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

By Dakin Helen Bentley Anthony Dusheiko Geoff

Value in Health, Vol. 13, Iss. 8, 2010-12 ,pp. : 922-933

Blackwell Publishing

Access to resources Recommend Favorite

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

By Dakin Helen Sherman Morris

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1075-1091

Adis International

Access to resources Recommend Favorite

Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

By Kim W. Ray Loomba Rohit Berg Thomas Aguilar Schall Raul E. Yee Leland J. Dinh Phillip V. Flaherty John F. Martins Eduardo B. Therneau Terry M. Jacobson Ira Fung Scott Gurel Selim Buti Maria Marcellin Patrick

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3631-3638

Blackwell Publishing

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Adis International Limited

Drugs in R&D, Vol. 5, Iss. 3, 2004-01 ,pp. : 160-161

Adis International

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Toni M. Dando Antona J. Wagstaff

Drugs, Vol. 64, Iss. 18, 2004-01 ,pp. : 2075-2082

Adis International

Access to resources Recommend Favorite